CEL-SCI Raises $5.7M via Stock Offering at $3.82/Share

CEL-SCI has announced the pricing of a $5.7 million offering, selling 1.5 million shares of common stock at $3.82 per share. The offering is priced at-the-market under NYSE American rules and is being conducted on a best-efforts basis. The proceeds from the offering will be used for general corporate purposes, including research and development.

Vienna, Va. - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has priced a best-efforts offering of 1.5 million shares of its common stock at $3.82 per share, generating approximately $5.7 million in gross proceeds [1]. The offering, priced at-the-market under NYSE American rules, is expected to close on July 14, 2025, subject to customary closing conditions. ThinkEquity is serving as the sole placement agent for the transaction.

The proceeds from the offering will be used to fund the continued development of CEL-SCI's investigational immunotherapy, Multikine, as well as for general corporate purposes and working capital. This funding comes at a crucial time as InvestingPro data indicates the company is quickly burning through cash, with a concerning current ratio of 0.55 indicating short-term obligations exceed liquid assets.

Multikine is designed to be administered before surgery, radiotherapy, and chemotherapy in patients with squamous cell carcinoma of the head and neck. The therapy has received Orphan Drug designation from the FDA for neoadjuvant therapy. The securities will be offered through a shelf registration statement filed with the SEC in July 2022.

CEL-SCI has also announced a partnership with a leading Saudi Arabian pharmaceutical company to advance the regulatory approval and commercialization of Multikine in Saudi Arabia. The Saudi partner will soon file a Breakthrough Medicine Designation application with the Saudi Food and Drug Authority (SFDA), which could expedite patient access to Multikine. Additionally, several Saudi investment funds have shown interest in investing in CEL-SCI, Multikine, or a potential joint venture for the Middle East and North Africa region [2].

The company is preparing for a confirmatory Registration Study with 212 patients, following the FDA’s agreement on patient selection criteria based on Phase 3 study data. The company continues to focus on enhancing patients’ immune systems before they are compromised by surgery, radiotherapy, and chemotherapy [3].

References:
[1] https://za.investing.com/news/company-news/celsci-prices-57-million-common-stock-offering-at-382-per-share-93CH-3787039
[2] https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176425207
[3] https://www.forbes.com/sites/martinadilicosa/2025/07/11/bezos-sells-109-million-more-amazon-shareswhile-honeymooning/